Mechanically, UCP2 promoted NSCLC progression by regulating the signaling pathway involving the mammalian target of rapamycin (mTOR) and hypoxia‐inducible factor‐1 alpha (HIF‐1α). Here, UCP2 is linked to non-small cell lung carcinoma.